PMC:7228307 / 42386-42656 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"716","span":{"begin":87,"end":94},"obj":"Gene"},{"id":"717","span":{"begin":130,"end":138},"obj":"Gene"},{"id":"721","span":{"begin":198,"end":205},"obj":"Species"},{"id":"723","span":{"begin":263,"end":269},"obj":"Disease"}],"attributes":[{"id":"A716","pred":"tao:has_database_id","subj":"716","obj":"Gene:2214"},{"id":"A717","pred":"tao:has_database_id","subj":"717","obj":"Gene:2214"},{"id":"A721","pred":"tao:has_database_id","subj":"721","obj":"Tax:9606"},{"id":"A723","pred":"tao:has_database_id","subj":"723","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T70","span":{"begin":263,"end":269},"obj":"Disease"}],"attributes":[{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T762","span":{"begin":87,"end":89},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T763","span":{"begin":112,"end":114},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T764","span":{"begin":130,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"716","span":{"begin":87,"end":94},"obj":"Gene"},{"id":"717","span":{"begin":130,"end":138},"obj":"Gene"},{"id":"721","span":{"begin":198,"end":205},"obj":"Species"},{"id":"723","span":{"begin":263,"end":269},"obj":"Disease"}],"attributes":[{"id":"A716","pred":"pubann:denotes","subj":"716","obj":"Gene:2214"},{"id":"A717","pred":"pubann:denotes","subj":"717","obj":"Gene:2214"},{"id":"A721","pred":"pubann:denotes","subj":"721","obj":"Tax:9606"},{"id":"A723","pred":"pubann:denotes","subj":"723","obj":"MESH:D009369"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T239","span":{"begin":0,"end":270},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T26","span":{"begin":263,"end":269},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T16","span":{"begin":263,"end":269},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-sentences","denotations":[{"id":"T239","span":{"begin":0,"end":270},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":263,"end":269},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer."}